Are Pharmaids Pharma latest results good or bad?

Pharmaids Pharmaceuticals has reported its financial results for the quarter ending March 2025, highlighting some notable trends. The company's net sales for the latest six months reached Rs 9.48 crore, reflecting a year-on-year growth of 62.61%, indicating strong demand for its products. However, this positive sales trend is contrasted by a decline in profitability metrics.
Specifically, the profit after tax (PAT) for the quarter stands at Rs -4.00 crore, which represents a decline compared to the average PAT of the previous four quarters. Similarly, the profit before tax (PBT) has decreased to Rs -5.53 crore, further illustrating the challenges in profitability.

Additionally, the company has experienced a substantial rise in interest costs, with quarterly interest expenses reaching Rs 1.01 crore, marking a dramatic increase quarter on quarter. This surge in interest expenses suggests a significant increase in borrowings, complicating the financial outlook for Pharmaids.

The quarterly results also show a slight growth in net sales of 1.27% compared to the previous quarter, although the consolidated net profit has seen a notable decline of 104.15%. The operating profit margin remains negative, indicating ongoing operational challenges.

Overall, the financial data indicates that while Pharmaids Pharmaceuticals is achieving strong sales growth, it is facing significant hurdles in profitability and rising costs, leading to an adjustment in its evaluation.